Assertio (NASDAQ:ASRT) Announces Quarterly Earnings Results, Misses Estimates By $0.11 EPS

Assertio (NASDAQ:ASRT) issued its quarterly earnings results on Monday. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.11), Zacks reports. Assertio had a negative net margin of 54.46% and a positive return on equity of 3.79%.

Assertio Stock Up 0.9%

ASRT stock traded up $0.01 during midday trading on Monday, reaching $0.62. 298,554 shares of the company’s stock traded hands, compared to its average volume of 687,808. The firm’s fifty day moving average price is $0.66 and its 200-day moving average price is $0.81. The company has a quick ratio of 1.57, a current ratio of 2.01 and a debt-to-equity ratio of 0.30. Assertio has a 52 week low of $0.51 and a 52 week high of $1.80. The company has a market cap of $58.94 million, a price-to-earnings ratio of -0.84, a P/E/G ratio of 3.25 and a beta of 0.32.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. StockNews.com upgraded shares of Assertio from a “hold” rating to a “buy” rating in a report on Monday, April 14th. Industrial Alliance Securities set a $1.75 price target on shares of Assertio in a research report on Friday, March 14th. Finally, HC Wainwright lowered their price target on Assertio from $4.00 to $3.50 and set a “buy” rating on the stock in a report on Wednesday, March 19th.

About Assertio

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.